A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease
2020-07-04
عنوان الدراسة
A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease
داعم الدراسة
Janssen-Cilag International NV
دواء الدراسة
Guselkumab
رقم بروتوكول الدراسة
CNTO1959CRD3001
حالة الدراسة
Ongoing
موقع الدراسة
King Abdullah Medical City (Makkah), King Abdulaziz Medical City NG (Riyadh)
مرحلة الدراسة
2
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。